Clinical-stage biopharmaceutical company EnGeneIC, which is developing its EDV nanocell platform for targeted cyto-immunotherapy in cancer, has won this year’s Drug Delivery Technology category in the Fierce Innovation Awards – LifeSciences Edition.
EDV is a cyto-immunotherapy that targets cancer cells as well as provoking a anti-tumour immune response.
According to Dr Jennifer MacDiarmid and Dr Himanshu Brahmbhatt, joint-CEOs and directors of EnGeneIC, “While we at EnGeneIC are all extremely honoured to be recognized with this award, we’re also pleased to announce that the 17th patient has been dosed in a Phase 1/2a clinical trial using EnGeneIC's EDVs to deliver a cytotoxic drug payload directly to tumours in patients who have exhausted curative treatment options.”
The company said the study is enrolling patients with advanced pancreatic cancer and other EGFR-expressing solid tumours in a second cohort.
All category winners were announced in the 2019 Innovation Report published by FierceHealthcare. Companies were evaluated based on effectiveness, technical innovation, competitive advantage, financial impact, and true innovation.